首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1379980

多癌症早期檢測市場，2028-全球產業規模、佔有率、趨勢、機會和預測，2018-2028 按類型、最終用戶、地區、競爭細分。

Multi Cancer Early Detection Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By End-user, By Region, By Competition.

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022年，全球多癌症早期檢測市場價值為8.4735億美元，預計到2028年，預測期內複合CAGR將達到9.13%。全球多癌症早期檢測市場近年來成長顯著，受到技術進步、意識增強以及對預防性醫療保健日益重視的推動。癌症的早期發現可以顯著改善患者的治療結果，使其成為醫療保健產業關注的關鍵領域。癌症仍然是全世界死亡的主要原因之一，每年有數百萬人喪生。早期檢測在提高癌症患者的生存率方面發揮關鍵作用，因為它可以實現及時干預和個人化治療計劃。全球多癌症早期檢測市場包含廣泛的診斷工具和技術，旨在在最早階段識別各種類型的癌症。

液體活體組織切片作為一種檢測體液中癌症生物標記的微創方法而受到重視。它提供了無需侵入性手術即可進行早期癌症檢測的潛力。人工智慧和機器學習演算法被用來分析大量患者資料，從而可以更精確地識別癌症相關模式和標記物。整合多種「組學」資料，例如基因組學、蛋白質組學和代謝組學，可以更全面地了解癌症和早期檢測。世界各地的政府和醫療機構擴大投資於癌症篩檢項目，以覆蓋更廣泛的人群並在早期階段檢測出癌症。

全球多癌症早期檢測市場預計將在未來幾年顯著成長。技術的進步、研發投資的增加以及人工智慧和大資料分析的整合預計將推動創新並提高癌症檢測方法的準確性。此外，患者和醫療保健提供者對早期癌症檢測重要性的認知不斷增強，將有助於市場擴張。政府和醫療保健組織可能會繼續支持旨在改善癌症篩檢和早期檢測計劃的措施。

市場概況
預測期	2024-2028
2022 年市場規模	8.4735億美元
2028 年市場規模	140578萬美元
2023-2028 年CAGR	9.13%
成長最快的細分市場	液體活體組織切片
最大的市場	北美洲

主要市場促進因素

癌症發生率上升正在推動全球多種癌症早期檢測市場

癌症仍然是全世界最重大的健康挑戰之一，多年來一直穩定上升。雖然癌症治療的進步提高了存活率，但早期檢測仍然是改善結果的關鍵因素。由於癌症發生率不斷上升，全球多癌症早期檢測市場正在大幅成長。癌症是一個嚴峻的全球健康問題，每年影響數百萬人。世界癌症研究基金會報告稱，癌症是全球第二大死因，估計僅 2020 年就有 1,000 萬人死亡。癌症的發生率因類型和地區而異，但一直呈上升趨勢。早期發現癌症對於提高存活率和減輕疾病負擔至關重要。當癌症在早期被發現時，它通常更容易治療，患者完全康復的機會也更高。然而，傳統的癌症篩檢方法通常僅限於特定類型的癌症，並且可能無法在最早、最可治療的階段檢測到癌症。

人口老化不斷成長正在推動全球多種癌症早期檢測市場

隨著全球人口老化，世界正在經歷重大的人口變化。隨著醫療保健的進步和生活水準的提高，人們的壽命比以往任何時候都更長。雖然這是一個積極的發展，但它也帶來了越來越多的擔憂——老年人癌症發病率上升。隨著人口老化不斷擴大，對有效癌症檢測和早期干預方法的需求激增，推動全球多癌症早期檢測市場邁向新高度。人口老化趨勢並不限於某一地區或國家；這是一個全球現象。據世界衛生組織(WHO) 稱，到2050 年，全球60 歲及以上人口預計將達到20 億，幾乎是2015 年的兩倍。這一轉變主要是由醫療保健改善、生活方式改變和出生率下降推動的在很多國家。然而，隨著預期壽命的延長，人們對各種與年齡相關的疾病（包括癌症）的易感性也隨之增加。

癌症通常被稱為衰老疾病。罹患癌症的風險隨著年齡的成長而顯著增加，大多數癌症病例發生在 65 歲及以上的人群中。隨著年齡的成長，他們的細胞會隨著時間的推移累積基因突變和損傷，使它們更容易發生癌變。此外，與年齡相關的免疫系統變化會削弱其檢測和破壞癌細胞的能力，從而導致腫瘤在未被發現的情況下發展。人口老化的人口結構變化對全球醫療保健系統產生了深遠的影響。它不僅使醫療資源緊張，而且還強調了早期癌症檢測的重要性，因為早期干預可以顯著改善患者的治療效果並降低治療成本。

傳統上，癌症檢測依賴於針對特定類型癌症的篩檢方法，例如乳癌的乳房X光檢查或大腸癌的大腸鏡檢查。然而，隨著人口老化的持續成長以及患多種癌症的風險增加，迫切需要更全面的癌症篩檢方法。多種癌症早期檢測測試正在成為應對這項挑戰的有希望的解決方案。這些測試旨在使用單一血液樣本或其他生物標記同時篩檢多種類型的癌症。他們利用基因組學、蛋白質組學和人工智慧等先進技術來識別早期癌症的存在，通常是在症狀出現之前。

主要市場挑戰

敏感性和特異性

多種癌症早期檢測的最重大挑戰之一是在診斷測試中實現高靈敏度和特異性。許多現有的測試可能會產生假陽性或遺漏早期癌症，導致患者不必要的焦慮或延遲診斷。開發能夠可靠區分癌症和非癌症疾病的高精度測試仍然是一項艱鉅的挑戰。

生物標記鑑定

多種癌症的早期檢測在很大程度上依賴於識別表明癌症存在的可靠生物標記。尋找特定於某些癌症類型且存在於疾病早期階段的生物標記是一項複雜且持續的研究工作。這些生物標記的發現和驗證需要大量的資源和時間。

成本和可及性

尖端多癌症篩檢測試的開發通常需要高昂的研發成本。這些成本經常轉嫁給消費者，使得大部分人無法進行這些測試。確保更廣泛的人群的負擔能力和可近性對於早期檢測方法的廣泛採用至關重要。

成本和可及性

監管障礙

對於多癌症早期檢測市場的公司來說，應對複雜的法規核准環境是另一個重大挑戰。美國 FDA 等監管機構對新的診斷測試有嚴格的要求，這可能會大大延遲市場准入。公司必須投入大量時間和資源來滿足這些監管標準。

資料隱私和安全

多種癌症的早期檢測通常依賴大量的患者資料，包括遺傳資訊。確保這些資料的隱私和安全至關重要，但也具有挑戰性，尤其是在資料外洩和隱私問題日益嚴重的世界中。建立符合 GDPR 和 HIPAA 等法規的強大資料保護系統是該行業的重要方面。

道德問題

多種癌症早期檢測的倫理影響是複雜的。誤報可能會導致不必要的治療和心理困擾，而誤報可能會帶來錯誤的安全感。確保個人充分了解這些測試的好處和局限性以及其結果的潛在後果是一項重大的道德挑戰。

患者意識和教育

許多人不知道多種癌症早期檢測測試的存在或潛在好處。提高患者意識並教育大眾了解早期癌症檢測的重要性是一項持續的挑戰。此外，克服對癌症篩檢的誤解和恐懼對於鼓勵參與至關重要。

與醫療保健系統整合

為了有效，多種癌症早期檢測方法需要無縫整合到現有的醫療保健系統中。這涉及與初級保健提供者、專家和腫瘤學家協調，以確保及時追蹤和治療。開發這種整合的框架並解決後勤挑戰可能很複雜。

主要市場趨勢

技術進步

近年來，醫療保健領域的技術進步堪稱革命性的。這些進步不僅改善了疾病的診斷和治療方式，而且使在疾病的早期階段發現和對抗疾病成為可能。受益於這些創新的最重要領域之一是全球多癌症早期檢測市場。隨著技術的不斷發展，它正在推動這個市場的擴張，為早期癌症檢測、診斷並最終改善患者的治療結果帶來新的希望。液體活體組織切片已成為癌症早期檢測的遊戲規則改變者。這些血液檢測可以檢測癌細胞釋放的 DNA 片段或其他分子，從而比傳統方法更早識別癌症。高靈敏度和特異性液體活體組織切片測試的發展正在推動多種癌症早期檢測的發展。事實證明，機器學習和人工智慧演算法在快速準確地分析大量醫療資料具有無價的價值。人工智慧驅動的工具可以識別醫學影像和患者記錄中的微妙模式和異常，有助於癌症的早期檢測和診斷。這項技術使得以以前無法達到的規模處理資訊成為可能。次世代定序 (NGS) 技術徹底改變了基因組分析，目前廣泛用於癌症研究。它可以對個體 DNA 進行全面分析，幫助識別與癌症相關的基因突變。這些資訊可用於早期檢測和個人化治療計劃。

生物標記發現的進步導致了與各種類型癌症相關的特定分子、蛋白質或遺傳標記的鑑定。這些生物標記可以在血液、尿液或組織樣本中檢測到，更容易同時篩檢多種癌症類型。遠距醫療獲得了巨大的關注，尤其是在 COVID-19 大流行之後。它可以實現遠端諮詢、監控，甚至收集重要的健康資料。該技術對於確保對有癌症風險或處於治療早期階段的個體進行及時追蹤特別有用。

細分市場洞察

類型洞察

根據類型類別，基因組、LDT 等將在 2022 年成為全球多癌症早期檢測市場的主導者。在快速發展的癌症診斷領域，基因組、LDT、液體活體組織切片和其他創新方法正在主導全球多癌症早期檢測市場。這些技術為癌症患者提供早期檢測、個人化治療和改善預後的潛力。隨著研究的繼續以及這些方法變得越來越廣泛，人們越來越有希望在未來癌症的早期階段得到有效的檢測和治療。

最終用途見解

預計醫院部門在預測期內將經歷快速成長。醫院通常擁有先進的診斷和實驗室設施，使其能夠進行全面、準確的多種癌症篩檢測試。他們可以投資尖端早期檢測方法所需的最新技術和設備。醫院擁有一支由醫療專業人員組成的多學科團隊，包括病理學家、腫瘤學家、放射科醫生和遺傳學家。這種專業知識對於解釋複雜的測試結果和指導患者完成診斷過程至關重要。

區域洞察

到 2022 年，歐洲將成為全球多癌症早期檢測市場的主導者，就價值而言佔據最大的市場佔有率。歐洲擁有蓬勃發展的生技產業，有許多公司致力於開發創新的癌症診斷技術。這些公司利用該地區熟練的勞動力、資金和有利的監管環境來推動尖端癌症篩檢技術的發展。羅氏 (Roche)、Exact Sciences 和 GRAIL 等著名歐洲公司處於多癌症早期檢測研究的前沿，生產的一系列產品獲得了全球認可。歐洲在多種癌症早期檢測市場中佔據主導地位的主要原因之一是其強大的研發生態系統。歐洲國家在投資醫學研究、促進創新以及與學術機構和生技公司合作方面有著悠久的歷史。這種對推動科學知識的承諾導致了用於早期癌症檢測的突破性技術和診斷工具的開發。

Grail, LLC（Illumina 公司）
- Business Overview
- Company Snapshot
- Products & Services
- Current Capacity Analysis
- Financials (In case of listed)
- Recent Developments
- SWOT Analysis
精確科學公司。
基礎醫學有限公司
安科迪克斯醫療有限公司
衛士健康公司
燃石生物科技有限公司
珍卡生物科技公司有限公司
先進醫學實驗室有限公司
鵜鶘遠基因公司

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄

Product Code: 17568

Global Multi Cancer Early Detection Market has valued at USD 847.35 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.13% through 2028. The global multi-cancer early detection market has witnessed remarkable growth in recent years, driven by advancements in technology, increased awareness, and a growing emphasis on preventive healthcare. Early detection of cancer can significantly improve patient outcomes, making it a critical area of focus in the healthcare industry. Cancer remains one of the leading causes of death worldwide, with millions of lives lost each year. Early detection plays a pivotal role in improving the survival rates of cancer patients, as it enables timely interventions and personalized treatment plans. The global multi-cancer early detection market encompasses a wide range of diagnostic tools and technologies designed to identify various types of cancer at the earliest stages.

Liquid biopsy has gained prominence as a minimally invasive method for detecting cancer biomarkers in bodily fluids. It offers the potential for early cancer detection without the need for invasive procedures. AI and machine learning algorithms are being used to analyze vast amounts of patient data, making it possible to identify cancer-related patterns and markers with higher precision. Integrating multiple 'omics' data, such as genomics, proteomics, and metabolomics, is enabling a more comprehensive understanding of cancer and early detection. Governments and healthcare organizations worldwide are increasingly investing in cancer screening programs to reach a broader population and detect cancer at earlier stages.

The global multi-cancer early detection market is poised for significant growth in the coming years. Advances in technology, increased investment in research and development, and the integration of AI and big data analytics are expected to drive innovation and improve the accuracy of cancer detection methods. Moreover, the growing awareness of the importance of early cancer detection among patients and healthcare providers will contribute to market expansion. Governments and healthcare organizations are likely to continue supporting initiatives aimed at improving cancer screening and early detection programs.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 847.35 Million
Market Size 2028	USD 1405.78 Million
CAGR 2023-2028	9.13%
Fastest Growing Segment	Liquid Biopsy
Largest Market	North America

Key Market Drivers

Rising Cancer Incidence Rates is Driving the Global Multi Cancer Early Detection Market

Cancer continues to be one of the most significant health challenges worldwide, with its incidence rates steadily rising over the years. While advances in cancer treatment have improved survival rates, early detection remains a critical factor in improving outcomes. The global multi-cancer early detection market is witnessing substantial growth as a result of the escalating cancer incidence rates. Cancer is a formidable global health issue, affecting millions of people each year. The World Cancer Research Fund reports that cancer is the second leading cause of death worldwide, responsible for an estimated 10 million deaths in 2020 alone. The incidence of cancer varies by type and region, but it is consistently on the rise. Early detection of cancer is essential for improving survival rates and reducing the burden of the disease. When cancer is detected at an early stage, it is often more treatable, and patients have a higher chance of achieving a complete recovery. However, traditional cancer screening methods are often limited to specific types of cancer and may not detect cancers at their earliest, most treatable stages.

Multi-cancer early detection represents a promising approach to addressing the rising cancer incidence rates. This approach involves the development of advanced diagnostic technologies and tests that can detect a wide range of cancer types simultaneously. Multi-cancer early detection allows for the simultaneous screening of numerous cancer types, including those without current effective screening methods. These tests are designed to be highly sensitive, increasing the chances of detecting cancer even at its earliest stages when treatment is most effective. Advanced algorithms and biomarkers are used to reduce false-positive results, ensuring that patients receive timely and accurate diagnoses. Identifying cancer at an early stage allows for timely intervention and personalized treatment plans, potentially saving lives. Multi-cancer early detection tests often require simple blood draws or urine samples, making them more accessible and less invasive than traditional screening methods like colonoscopies or mammograms.

The global multi-cancer early detection market is experiencing rapid growth, with numerous companies investing in research and development to create innovative screening solutions. Investors, governments, and healthcare organizations recognize the potential benefits of these technologies in reducing cancer-related morbidity and mortality. As the market expands, it is likely to become more affordable and accessible to a broader population, further enhancing its impact on reducing cancer deaths. Regulatory bodies are also working to establish guidelines and approval pathways for these new diagnostic tools, ensuring their safety and efficacy.

Growing Aging Population is Driving the Global Multi Cancer Early Detection Market

The world is experiencing a significant demographic shift as the global population ages. With advancements in healthcare and improvements in living standards, people are living longer lives than ever before. While this is a positive development, it also brings with it a growing concern - the rise in cancer incidence among the elderly. As the aging population continues to expand, the demand for effective cancer detection and early intervention methods has surged, propelling the global multi-cancer early detection market to new heights. The aging population trend is not limited to one region or country; it is a global phenomenon. According to the World Health Organization (WHO), by 2050, the global population aged 60 and over is expected to reach 2 billion, nearly double the number in 2015. This shift is primarily driven by improved healthcare, lifestyle changes, and declining birth rates in many countries. However, along with increased life expectancy comes an increased susceptibility to various age-related diseases, including cancer.

Cancer is often referred to as a disease of aging. The risk of developing cancer significantly increases with age, with most cancer cases occurring in individuals aged 65 and older. As people age, their cells accumulate genetic mutations and damage over time, making them more prone to cancerous growth. Additionally, age-related changes in the immune system can impair its ability to detect and destroy cancer cells, allowing tumors to develop undetected. This aging population demographic shift has had a profound impact on healthcare systems worldwide. Not only does it strain healthcare resources, but it also underscores the importance of early cancer detection, as early intervention can significantly improve patient outcomes and reduce treatment costs.

Traditionally, cancer detection relied on screening methods that targeted specific types of cancer, such as mammograms for breast cancer or colonoscopies for colorectal cancer. However, as the aging population continues to grow and the risk of developing multiple types of cancer increases, there is a pressing need for a more comprehensive approach to cancer screening. Multi-cancer early detection tests are emerging as a promising solution to this challenge. These tests are designed to simultaneously screen for multiple types of cancer using a single blood sample or other biomarkers. They leverage advanced technologies such as genomics, proteomics, and artificial intelligence to identify the presence of cancer in its early stages, often before symptoms manifest.

Key Market Challenges

Sensitivity and Specificity

One of the most significant challenges in multi-cancer early detection is achieving high sensitivity and specificity in diagnostic tests. Many existing tests may produce false positives or miss early-stage cancers, leading to unnecessary anxiety for patients or delayed diagnoses. Developing highly accurate tests that can reliably distinguish between cancer and non-cancer conditions remains a formidable challenge.

Biomarker Identification

Multi-cancer early detection relies heavily on the identification of reliable biomarkers that signal the presence of cancer. Finding biomarkers that are both specific to certain cancer types and present in the early stages of the disease is a complex and ongoing research endeavor. The discovery and validation of these biomarkers require substantial resources and time.

Cost and Accessibility

The development of cutting-edge multi-cancer screening tests often comes with high research and development costs. These costs are frequently passed on to consumers, making these tests inaccessible to large portions of the population. Ensuring affordability and accessibility for a broader demographic is essential for the widespread adoption of early detection methods.

Cost and Accessibility

Regulatory Hurdles

Navigating the complex landscape of regulatory approvals is another major challenge for companies in the multi-cancer early detection market. Regulatory bodies like the FDA in the United States have stringent requirements for new diagnostic tests, which can significantly delay market entry. Companies must invest significant time and resources to meet these regulatory standards.

Data Privacy and Security

Multi-cancer early detection often relies on vast amounts of patient data, including genetic information. Ensuring the privacy and security of this data is crucial but challenging, especially in a world where data breaches and privacy concerns are on the rise. Building robust data protection systems that comply with regulations like GDPR and HIPAA is a critical aspect of the industry.

Ethical Concerns

The ethical implications of multi-cancer early detection are complex. False positives can lead to unnecessary treatments and psychological distress, while false negatives may provide a false sense of security. Ensuring that individuals are adequately informed about the benefits and limitations of these tests and the potential consequences of their results is a significant ethical challenge.

Patient Awareness and Education

Many individuals are not aware of the existence or potential benefits of multi-cancer early detection tests. Increasing patient awareness and educating the public about the importance of early cancer detection is a continuous challenge. Additionally, overcoming misconceptions and fear surrounding cancer screening is essential to encourage participation.

Integration with Healthcare Systems

To be effective, multi-cancer early detection methods need to be integrated seamlessly into existing healthcare systems. This involves coordinating with primary care providers, specialists, and oncologists to ensure timely follow-up and treatment. Developing a framework for this integration and addressing logistical challenges can be complex.

Key Market Trends

Technological Advancements

In recent years, technological advancements in the field of healthcare have been nothing short of revolutionary. These advancements are not only improving the way diseases are diagnosed and treated but are also making it possible to detect and combat diseases at their earliest stages. One of the most significant areas benefiting from these innovations is the global multi-cancer early detection market. As technology continues to evolve, it is driving the expansion of this market, offering new hope for early cancer detection, diagnosis, and ultimately, improved patient outcomes. Liquid biopsies have emerged as a game-changer in the early detection of cancer. These blood tests can detect fragments of DNA or other molecules released by cancer cells, allowing for the identification of cancer at an earlier stage than traditional methods. The development of highly sensitive and specific liquid biopsy tests is driving the growth of multi-cancer early detection. Machine learning and AI algorithms have proven invaluable in analyzing vast amounts of medical data quickly and accurately. AI-powered tools can identify subtle patterns and anomalies in medical images and patient records, aiding in the early detection and diagnosis of cancer. This technology is making it possible to process information at a scale that was previously unattainable. Next-Generation Sequencing (NGS) technology has revolutionized genomic analysis and is now being used extensively in cancer research. It allows for the comprehensive analysis of an individual's DNA, helping to identify genetic mutations associated with cancer. This information can be used for early detection and personalized treatment plans.

Advances in biomarker discovery have led to the identification of specific molecules, proteins, or genetic markers that are associated with various types of cancer. These biomarkers can be detected in blood, urine, or tissue samples, making it easier to screen for multiple cancer types simultaneously. Telemedicine has gained significant traction, especially in the wake of the COVID-19 pandemic. It enables remote consultations, monitoring, and even the collection of vital health data. This technology is particularly useful in ensuring timely follow-ups for individuals at risk of cancer or those in the early stages of treatment.

Segmental Insights

Type Insights

Based on the category of Type, the gene panel, LDT, and others emerged as the dominant player in the global market for Multi Cancer Early Detection in 2022. In the rapidly evolving landscape of cancer diagnosis, gene panels, LDTs, liquid biopsies, and other innovative approaches are dominating the global multi-cancer early detection market. These technologies offer the potential for earlier detection, personalized treatment, and improved outcomes for cancer patients. As research continues and these methods become more widely available, the hope for a future where cancer is detected and treated effectively at its earliest stages becomes increasingly attainable.

End Use Insights

The hospitals segment is projected to experience rapid growth during the forecast period. Hospitals typically possess advanced diagnostic and laboratory facilities, allowing them to conduct comprehensive and accurate multi-cancer screening tests. They can invest in the latest technologies and equipment required for cutting-edge early detection methods. Hospitals house a multidisciplinary team of medical professionals, including pathologists, oncologists, radiologists, and geneticists. This expertise is crucial for interpreting complex test results and guiding patients through the diagnostic process.

Regional Insights

Europe emerged as the dominant player in the global Multi Cancer Early Detection market in 2022, holding the largest market share in terms of value. Europe boasts a thriving biotechnology industry, with numerous companies dedicated to developing innovative cancer diagnostics. These companies leverage the region's skilled workforce, access to funding, and favorable regulatory environment to drive the development of cutting-edge cancer screening technologies. Notable European companies like Roche, Exact Sciences, and GRAIL are at the forefront of multi-cancer early detection research, producing a range of products that are gaining global recognition. One of the primary reasons for Europe's prominence in the multi-cancer early detection market is its robust research and development ecosystem. European countries have a long history of investing in medical research, fostering innovation, and collaborating with academic institutions and biotech companies. This commitment to advancing scientific knowledge has led to the development of groundbreaking technologies and diagnostic tools for early cancer detection.

Key Market Players

Grail, LLC (Illumina, Inc.)

Exact Sciences Corporation.

Foundation Medicine, Inc.

AnchorDx Medical Co Ltd

Guardant Health, Inc.

Burning Rock Biotech Limited

genecast biotechnology co. ltd

Laboratory for Advanced Medicine, Inc.

Singlera Genomics Inc.

Report Scope:

In this report, the Global Multi Cancer Early Detection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multi Cancer Early Detection Market, By Type:

Gene Panel
LDT & Others Surgical

Multi Cancer Early Detection Market, By End User:

Hospitals
Diagnostic Laboratories
Others

Multi Cancer Early Detection Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multi Cancer Early Detection Market.

Available Customizations:

Global Multi Cancer Early Detection market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Multi Cancer Early Detection Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Liquid Biopsy, Gene Panel, LDT & Others)
- 5.2.2. By End-user (Hospitals, Diagnostic Laboratories, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Market Map

6. North America Multi Cancer Early Detection Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End-user
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Multi Cancer Early Detection Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End-user
- 6.3.2. Canada Multi Cancer Early Detection Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End-user
- 6.3.3. Mexico Multi Cancer Early Detection Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End-user

7. Europe Multi Cancer Early Detection Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End-user
7.3. Europe: Country Analysis
- 7.3.1. Germany Multi Cancer Early Detection Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End-user
- 7.3.2. United Kingdom Multi Cancer Early Detection Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
- 7.3.3. Italy Multi Cancer Early Detection Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End-user
- 7.3.4. France Multi Cancer Early Detection Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By End-user
- 7.3.5. Spain Multi Cancer Early Detection Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By End-user

8. Asia-Pacific Multi Cancer Early Detection Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End-user
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Multi Cancer Early Detection Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End-user
- 8.3.2. India Multi Cancer Early Detection Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End-user
- 8.3.3. Japan Multi Cancer Early Detection Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End-user
- 8.3.4. South Korea Multi Cancer Early Detection Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By End-user
- 8.3.5. Australia Multi Cancer Early Detection Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By End-user

9. South America Multi Cancer Early Detection Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End-user
9.3. South America: Country Analysis
- 9.3.1. Brazil Multi Cancer Early Detection Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End-user
- 9.3.2. Argentina Multi Cancer Early Detection Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End-user
- 9.3.3. Colombia Multi Cancer Early Detection Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End-user

10. Middle East and Africa Multi Cancer Early Detection Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By End-user
10.3. MEA: Country Analysis
- 10.3.1. South Africa Multi Cancer Early Detection Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By End-user
- 10.3.2. Saudi Arabia Multi Cancer Early Detection Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End-user
- 10.3.3. UAE Multi Cancer Early Detection Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End-user

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition
12.2. Type Development
12.3. Recent Developments

13. Global Multi Cancer Early Detection Market: SWOT Analysis

14. Competitive Landscape

14.1 Grail, LLC (Illumina, Inc.)
- 14.1.1 Business Overview
- 14.1.2 Company Snapshot
- 14.1.3 Products & Services
- 14.1.4 Current Capacity Analysis
- 14.1.5 Financials (In case of listed)
- 14.1.6 Recent Developments
- 14.1.7 SWOT Analysis
14.2 Exact Sciences Corporation.
14.3 Foundation Medicine, Inc.
14.4 AnchorDx Medical Co Ltd
14.5 Guardant Health, Inc.
14.6 Burning Rock Biotech Limited
14.7 genecast biotechnology co. ltd
14.8 Laboratory for Advanced Medicine, Inc.
14.9 Singlera Genomics Inc.